Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.

Bettayeb K, Baunbæk D, Delehouze C, Loaëc N, Hole AJ, Baumli S, Endicott JA, Douc-Rasy S, Bénard J, Oumata N, Galons H, Meijer L.

Genes Cancer. 2010 Apr;1(4):369-80. doi: 10.1177/1947601910369817.

2.

The selective P-TEFb inhibitor CAN508 targets angiogenesis.

Kryštof V, Rárová L, Liebl J, Zahler S, Jorda R, Voller J, Cankař P.

Eur J Med Chem. 2011 Sep;46(9):4289-94. doi: 10.1016/j.ejmech.2011.06.035. Epub 2011 Jul 3.

PMID:
21777997
3.

CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.

Liu X, Shi S, Lam F, Pepper C, Fischer PM, Wang S.

Int J Cancer. 2012 Mar 1;130(5):1216-26. doi: 10.1002/ijc.26127. Epub 2011 Jun 21.

4.

Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.

Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J.

Mol Cell. 2011 Apr 8;42(1):9-22. doi: 10.1016/j.molcel.2011.03.004. Review.

5.

Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.

Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS.

Leuk Res. 2011 Jun;35(6):821-30. doi: 10.1016/j.leukres.2010.12.010. Epub 2011 Jan 8.

PMID:
21216463
6.

Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

Wang S, Griffiths G, Midgley CA, Barnett AL, Cooper M, Grabarek J, Ingram L, Jackson W, Kontopidis G, McClue SJ, McInnes C, McLachlan J, Meades C, Mezna M, Stuart I, Thomas MP, Zheleva DI, Lane DP, Jackson RC, Glover DM, Blake DG, Fischer PM.

Chem Biol. 2010 Oct 29;17(10):1111-21. doi: 10.1016/j.chembiol.2010.07.016.

7.

Halogen bonds form the basis for selective P-TEFb inhibition by DRB.

Baumli S, Endicott JA, Johnson LN.

Chem Biol. 2010 Sep 24;17(9):931-6. doi: 10.1016/j.chembiol.2010.07.012.

8.

Crystal structure of HIV-1 Tat complexed with human P-TEFb.

Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH.

Nature. 2010 Jun 10;465(7299):747-51. doi: 10.1038/nature09131.

9.

Pharmacological targeting of CDK9 in cardiac hypertrophy.

Krystof V, Chamrád I, Jorda R, Kohoutek J.

Med Res Rev. 2010 Jul;30(4):646-66. doi: 10.1002/med.20172. Review.

PMID:
19757441
10.

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W.

Blood. 2009 May 7;113(19):4637-45. doi: 10.1182/blood-2008-12-190256. Epub 2009 Feb 20.

11.

Targeting cancer with small molecule kinase inhibitors.

Zhang J, Yang PL, Gray NS.

Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559. Review.

PMID:
19104514
12.

The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation.

Baumli S, Lolli G, Lowe ED, Troiani S, Rusconi L, Bullock AN, Debreczeni JE, Knapp S, Johnson LN.

EMBO J. 2008 Jul 9;27(13):1907-18. doi: 10.1038/emboj.2008.121. Epub 2008 Jun 19.

13.

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.

Wang S, Fischer PM.

Trends Pharmacol Sci. 2008 Jun;29(6):302-13. doi: 10.1016/j.tips.2008.03.003. Epub 2008 Apr 16. Review.

PMID:
18423896
14.

A novel anticancer agent ARC antagonizes HIV-1 and HCV.

Nekhai S, Bhat UG, Ammosova T, Radhakrishnan SK, Jerebtsova M, Niu X, Foster A, Layden TJ, Gartel AL.

Oncogene. 2007 May 31;26(26):3899-903. Epub 2006 Dec 18.

PMID:
17173067
15.

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF Jr, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M.

J Med Chem. 2006 Nov 2;49(22):6500-9.

PMID:
17064068
16.

Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination.

Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ Jr, Wasney GA, Yeung R, Arrowsmith C, Ball LJ, Berglund H, Hui R, Marsden BD, Nordlund P, Sundstrom M, Weigelt J, Edwards AM.

Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15835-40. Epub 2006 Oct 11.

17.

The conformational plasticity of protein kinases.

Huse M, Kuriyan J.

Cell. 2002 May 3;109(3):275-82. Review.

18.

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.

Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM.

Genome Biol. 2001;2(10):RESEARCH0041. Epub 2001 Sep 13.

19.

The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.

Brown NR, Noble ME, Endicott JA, Johnson LN.

Nat Cell Biol. 1999 Nov;1(7):438-43.

PMID:
10559988

Supplemental Content

Support Center